As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a
most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma …

Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various
receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib …

Background First-line sunitinib is recommended in metastatic renal cell carcinoma (mRCC),
but it is frequently associated with relevant toxicities and subsequent dose reductions …

The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …

Background The standard sunitinib schedule, 4 weeks on, followed by 2 weeks off (4/2
schedule), is associated with troublesome toxicities, and maintenance of adequate sunitinib …

Background Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment
of metastatic renal cell carcinoma (mRCC). However, how the efficacy of these drugs …

Background Cancer cachexia is associated with patient outcomes. Objective The objective
was to evaluate the effect of cachexia on survival among patients with metastatic renal cell …

Introduction: Small molecule protein kinase inhibitors (KIs) are a class of drugs with complex
and unconventional physiochemical and pharmacokinetic characteristics. Cytochrome P450 …

The use of targeted therapy (TT) has radically changed the outcome of various cancers and
introduces the era of personalised medicine. Elderly patients (≥ 65 years) represent the …

Introduction: Sunitinib is a multi-target, anti-angiogenic tyrosine kinase inhibitor and a key
molecule in the treatment of metastatic renal cell carcinoma (mRCC). Since it first …